

Interviews Released on Antibiotic Resistance with BARDA, Janssen and Blueberry Therapeutics

SMi Group release an exclusive series of interviews ahead of the Superbugs & Superdrugs USA Conference taking place on Nov 14th and 15th

LONDON, ENGLAND, UNITED KINGDOM, September 23, 2016 /EINPresswire.com/ -- Running for 18 years in Europe, SMi Group's <u>Superbugs</u> & <u>Superdrugs</u> event will travel across the Atlantic Ocean for the first time to Iselin New Jersey following a high attendance of US delegates at the European show. The popularity of the event highlights the imminent global threat of antimicrobial resistance and the urgency for scientists and drug developers to discover new alternatives to bacteria resistant treatments.

The interviews released this week with 3 of the keynote speakers are available in the event download centre at <u>www.superbugs-usa.com</u>

Dr. Christopher Houchens, Branch Chief of the Antibacterials Program at the US Government Federal Agency, BARDA, said:

"Attendees will gain a deeper understanding of BARDA's mission, why it is focused on supporting the research



NOV 14-15 2016 Iselin, New Jersey

www.superbugs-usa.com

Superbugs USA 2016

and development of products for addressing AMR, BARDA's current priorities and future objectives, and how interested product developers and sponsors can partner with BARDA to achieve our mutual goals of bringing new products to the market that are effective in the treatment of drug-resistant bacterial infections."

Senior Scientific Director, Dr Anthony Simon Lynch from Janssen Research & Development commented:

"The three sessions focused on novel platforms and agents in the treatment and prevention of

٢٢

...it's always good to be cognizant of new science and potential opportunities Janssen diseases caused by so-called 'Superbugs' are all of interest as they cover a broad spectrum of alternate approaches and it's always good to be cognizant of new science and potential opportunities."

Providing a European perspective to the show, Dr David Cook, Chief Scientific Officer from Blueberry Therapeutics said:

"I'm looking forward to the section on "Strengthening the Pipeline" and hearing about the other work going on in developing beta-lactamase inhibitors."

All three interview are available to read online here.

Superbugs & Superdrugs USA November 14th & 15th 2016 Renaissance Woodbridge Hotel, Iselin, New Jersey Sponsored by Noigel, LLC and Polyphor <u>www.superbugs-usa.com</u>

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk To register for the conference, visit <u>www.superbugs-usa.com</u> or contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

---END----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group 2078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2016 IPD Group, Inc. All Right Reserved.